S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
NYSE:ENOV

Enovis (ENOV) Stock Forecast, Price & News

$52.59
-0.29 (-0.55%)
(As of 02:33 PM ET)
Compare
Today's Range
$51.53
$53.17
50-Day Range
$51.67
$65.50
52-Week Range
$43.88
$66.71
Volume
508,453 shs
Average Volume
395,386 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.29

Enovis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.3% Upside
$65.29 Price Target
Short Interest
Bearish
5.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Enovis in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$14,674 Sold Last Quarter
Proj. Earnings Growth
16.81%
From $2.26 to $2.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

515th out of 963 stocks

Surgical Appliances & Supplies Industry

11th out of 17 stocks


ENOV stock logo

About Enovis (NYSE:ENOV) Stock

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Price History

ENOV Stock News Headlines

Enovis to acquire LimaCorporate in $847m deal
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
EQT to Sell LimaCorporate to Enovis
Enovis to Buy LimaCorporate in $850 Million Deal >ENOV
Enovis Announces Acquisition Of LimaCorporate - Quick Facts
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Enovis to Acquire LimaCorporate S.p.A.
Should You Invest in Enovis Corporation (ENOV)?
Enovis to Participate in Upcoming Investor Conferences
Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.29
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$57.00
Forecasted Upside/Downside
+24.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-13,290,000.00
Pretax Margin
-8.00%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$6.16 per share
Book Value
$63.71 per share

Miscellaneous

Free Float
51,758,000
Market Cap
$2.87 billion
Optionable
Optionable
Beta
2.05
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Matthew L. Trerotola (Age 56)
    CEO & Chairman
    Comp: $5.12M
  • Mr. Brady R. Shirley (Age 57)
    Pres, COO & Director
    Comp: $3.34M
  • Ms. Patricia A. Lang (Age 64)
    Sr. VP & Chief HR Officer
    Comp: $1.59M
  • Mr. Daniel A. Pryor (Age 55)
    Exec. VP of Strategy & Bus. Devel.
    Comp: $2.08M
  • Mr. Phillip Benjamin Berry (Age 44)
    Sr. VP & CFO
  • Mr. John Kleckner (Age 46)
    VP, Controller & Chief Accounting Officer
  • Derek Leckow
    VP of Investor Relations
  • Mr. Bradley J. Tandy (Age 64)
    Sr. VP & Gen. Counsel
  • Katie Sweet
    VP of Corp. Communication
  • Brian P. Hanigan
    Sec.













ENOV Stock - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings
or view top-rated stocks.

What is Enovis' stock price forecast for 2023?

6 analysts have issued twelve-month price targets for Enovis' stock. Their ENOV share price forecasts range from $57.00 to $70.00. On average, they anticipate the company's share price to reach $65.29 in the next year. This suggests a possible upside of 24.1% from the stock's current price.
View analysts price targets for ENOV
or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2023?

Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV stock has decreased by 1.7% and is now trading at $52.59.
View the best growth stocks for 2023 here
.

Are investors shorting Enovis?

Enovis saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,690,000 shares, an increase of 10.2% from the August 15th total of 2,440,000 shares. Based on an average trading volume of 357,800 shares, the short-interest ratio is presently 7.5 days. Approximately 5.4% of the shares of the stock are short sold.
View Enovis' Short Interest
.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ENOV earnings forecast
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) issued its earnings results on Thursday, August, 3rd. The company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.08. The business earned $428.50 million during the quarter, compared to the consensus estimate of $420.06 million. Enovis had a positive trailing twelve-month return on equity of 3.74% and a negative net margin of 8.52%. The company's revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS.

What ETFs hold Enovis' stock?
What guidance has Enovis issued on next quarter's earnings?

Enovis issued an update on its FY 2023 earnings guidance on Friday, September, 22nd. The company provided earnings per share (EPS) guidance of $2.22-$2.36 for the period, compared to the consensus estimate of $2.31. The company issued revenue guidance of -.

What is Enovis' stock symbol?

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Who are Enovis' major shareholders?

Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.10%), Dimensional Fund Advisors LP (5.44%), Diamond Hill Capital Management Inc. (4.05%), Thrivent Financial for Lutherans (3.25%), State Street Corp (2.81%) and Durable Capital Partners LP (2.79%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends
.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enovis' stock price today?

One share of ENOV stock can currently be purchased for approximately $52.59.

How much money does Enovis make?

Enovis (NYSE:ENOV) has a market capitalization of $2.87 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Enovis have?

The company employs 6,800 workers across the globe.

How can I contact Enovis?

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.

This page (NYSE:ENOV) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -